Cardiff Oncology Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
CRDF$0.80+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
| Preferred StockShares | Preferred StockAmount | Common StockShares | Common StockAmount | Additional Paid-In Capital | Accumulated Other Comprehensive Loss | Accumulated Deficit | TotalStockholders’ Equity | |
|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2023 | 61 | $— | 44,677 | $4 | $409,343 | $(67) | $(339,541) | $69,739 |
| Modified-retrospective adoption of ASU 2020-06(1) | — | — | — | — | (793) | — | 793 | — |
| Stock-based compensation | — | — | — | — | 1,124 | — | — | 1,124 |
| Issuance of common stock upon exercise of stock options | — | — | 33 | — | 107 | — | — | 107 |
| Other comprehensive loss | — | — | — | — | — | (65) | — | (65) |
| Net loss | — | — | — | — | — | — | (10,011) | (10,011) |
| Balance, March 31, 2024 | 61 | — | 44,710 | 4 | 409,781 | (132) | (348,759) | 60,894 |
| Issuance of common stock, net of expenses(2) | — | — | 792 | 1 | 1,804 | — | — | 1,805 |
| Stock-based compensation | — | — | — | — | 1,179 | — | — | 1,179 |
| Issuance of common stock upon exercise of stock options | — | — | 100 | — | 253 | — | — | 253 |
| Other comprehensive gain | — | — | — | — | — | 35 | — | 35 |
| Net loss | — | — | — | — | — | — | (11,778) | (11,778) |
| Balance, June 30, 2024 | 61 | $— | 45,602 | $5 | $413,017 | $(97) | $(360,537) | $52,388 |
(1)See Note 2.
(2)Net of expenses of $197,000.
| Preferred StockShares | Preferred StockAmount | Common StockShares | Common StockAmount | Additional Paid-In Capital | Accumulated Other Comprehensive Loss | Accumulated Deficit | TotalStockholders’ Equity | |
|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2022 | 61 | $— | 44,677 | $4 | $404,834 | $(395) | $(298,100) | $106,343 |
| Stock-based compensation | — | — | — | — | 1,064 | — | — | 1,064 |
| Other comprehensive gain | — | — | — | — | — | 319 | — | 319 |
| Net loss | — | — | — | — | — | — | (11,223) | (11,223) |
| Balance, March 31, 2023 | 61 | — | 44,677 | 4 | 405,898 | (76) | (309,323) | 96,503 |
| Stock-based compensation | — | — | — | — | 1,581 | — | — | 1,581 |
| Other comprehensive loss | — | — | — | — | — | (355) | — | (355) |
| Net loss | — | — | — | — | — | — | (11,150) | (11,150) |
| Balance, June 30, 2023 | 61 | $— | 44,677 | $4 | $407,479 | $(431) | $(320,473) | $86,579 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.